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ABSTRACT
Both the ERCC1-XPF complex and the proteins
involved in homoIogous recombination (HR) have
critical roles in inter-strand cross-link (ICL) repair.
Here, we report that mitomycin C-induced lesions
inhibit replication fork elongation. Furthermore,
mitomycin C-induced DNA double-strand breaks
(DSBs) are the result of the collapse of ICL-stalled
replication forks. These are not formed through rep-
lication run off, as we show that mitomycin C or
cisplatin-induced DNA lesions are not incised by
global genome nucleotide excision repair (GGR).
We also suggest that ICL-lesion repair is initiated
either by replication or transcription, as the GGR
does not incise ICL-lesions. Furthermore, we
report that RAD51 foci are induced by cisplatin or
mitomycin C independently of ERCC1, but that
mitomycin C-induced HR measured in a reporter
construct is impaired in ERCC1-defective cells.
These data suggest that ERCC1–XPF plays a role
in completion of HR in ICL repair. We also find
no additional sensitivity to cisplatin by siRNA
co-depletion of XRCC3 and ERCC1, showing that
the two proteins act on the same pathway to
promote survival.
INTRODUCTION
Inter-strand cross-link (ICL)-inducing agents cause a
unique class of DNA lesions that are extremely cytotoxic.
ICLs covalently modify both strands of the DNA, thus
preventing their separation and consequently blocking
transcription, segregation and replication (1). ICL agents
have been eﬀectively used in anticancer chemotherapy,
because their toxicity targets proliferating cells. Even
though a variety of DNA adducts can be produced by
cross-linking agents, their eﬀective cytotoxicity is related
to their capability of forming ICLs (2). Due to the com-
plexity of the ICL-induced DNA damage, repair machin-
ery that simply excises the damaged DNA and then uses
replication from a template for nucleotide replacement
is inadequate. This has been well demonstrated in
Escherichia coli and Saccharomyces cerevisiae, where
components of nucleotide excision repair (NER), homol-
ogous recombination (HR) and translesion synthesis
(TLS) are all required for adequate ICL repair (3,4).
However, it is shown that a replication and recombination
independent ICL repair machinery is active on transcribed
DNA (5,6).
HR and TLS are both needed for ICL repair in yeast
and higher eukaryotes, but not all NER proteins are
involved in ICL repair in mammals. Studies have
proposed that among all the NER proteins only ERCC1
and XPF play a key role in ICL repair (7). The ERCC1
protein forms a highly conserved endonuclease
heterodimeric complex with XPF (8) that stabilizes both
proteins for their role in DNA repair (9,10). In mamma-
lian cells, this structure-speciﬁc heterodimeric endo-
nuclease complex, ERCC1-XPF, is recruited by XPA
to the damaged DNA site (11) to create a nick at the 50
side of the helix-distorting lesion. A structure speciﬁc
endonuclease, XPG, compliments ERCC1-XPF by
nicking the DNA on the other side of the lesion, thus
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cleave many DNA structures, including bubbles, stem–
loops, splayed arms and ﬂaps (13–15). Importantly, mam-
malian XPG mutants were shown to be less sensitive to
ICL damage when compared to ERCC1 and XPF
mutants (7,16) implying that ICL repair in mammals is
diﬀerent from ICL repair in lower eukaryotes, where
both endonuclease activities are necessary for eﬃcient
ICL repair (17).
Moreover, XPF patients’ cells were shown to
proﬁciently process ICLs but failed to deal with mono-
adducts via NER (18), suggesting that XPF functions in
ICL repair in an NER independent manner. The
ERCC1-XPF endonuclease complex has been reported
to cleave an artiﬁcial substrate on both sides of a crosslink
lesion, ﬂanking a single-stranded 30 ﬂap, induced by
psoralen (19). Therefore the ERCC1-XPF endonuclease
function was designated as the initiation of the strand
breaks adjacent to, and on each side of, the lesion in
one strand of the DNA during ICL repair, known as the
unhooking step. However, this contradicts cellular
ﬁndings that ICL-inducing agents cause the same
increased level of DNA double-strand break (DSB) for-
mation in ERCC1 and XPF mutant cells as in wild-type
cells (16,20). These ﬁndings suggest that ERCC1-XPF
functions after formation of the DSB. In addition to
their role in NER and ICL repair, the ERCC1–XPF
complex has been found to function in some sub-
pathways of homology-directed DSB repair, through
single-strand annealing, gene conversion and homologous
gene targeting (21–24).
The exact role of the ERCC1–XPF complex in ICL
repair is still under debate (25), although most data
suggest a link with HR, as discussed above. Here, we
use ERCC1-defective or siRNA-depleted cells to study
the role of the ERCC1–XPF complex and report that it
is involved in the late stage of HR during ICL repair,
but we also point to a role for ERCC1 in ICL repair
that is distinct from HR. Furthermore, we provide more
insight into the formation of replication-associated ICL-
induced DSBs.
MATERIALS AND METHODS
Cell lines
All cell lines used were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) supplemented with 10% fetal
calf serum, penicillin (60–100mg/ml), streptomycin
(100mg/ml) at 37 C containing 5% CO2, in a humidiﬁed
incubator. The medium was supplemented with
hygromycin (0.05mM) in order to maintain the DRneo
vector and SCneo vector, and Blasticidin (3mg/ml) to
maintain the PEf6-V5-His- ERCC1 and PEF6-V5-His-
Topo vector-containing cell lines. The 51D1SC.2,
51D1SC.4, AA8SN.6, AA8SN.10 and AA8SN.12 cell
lines were created following the electroporation of the
SCneo vector into the parental AA8 and Rad51D1
–/–
51D1 cells and isolation of individual clones as described
earlier (Table 1) (26). The SQ20B human head and neck
cancer cell line was obtained from ATCC.
Survival assays for hamster cells
Five hundred cells from each cell line (V-C8, V-C8+B2,
V79Z, AA8SN.10, AA8SN.12, 51D1SC.2, 51D1SC.4,
UV4DR7, ERCC1.17, ERCC1.21 and PEF7) were
seeded over night to be treated with diﬀerent doses of
MMC, cisplatin or melphalan on the following day.
After that they were incubated for 7–14 days in the
humidiﬁed 5% CO2/37 C incubator, the colonies were
ﬁxed and stained with 0.4% methylene blue in methanol
to be counted.
Table 1. Genotype and origin of Chinese hamster cell lines used in this study and IC50 values for mitomycin C (MMC), cisplatin and melphalan
Cell line Genotype Defect / modiﬁcation Origin IC50
[MMC]
(nM)
IC50
[cisplatin]
(nM)
IC50
[melphalan]
(nM)
Reference
51D1 RAD51D
 /  RAD51D knockout AA8 ND ND ND (26)
51D1SC.2, RAD51D
 /  Integrated SCneo 51D1 3.07 97.86 0.23 This study
51D1SC.4 recombination reporter (hyg
R) 3.44 116.10 ND
AA8 wt wt Ovary 238.98 ND 6.94 (35)
AA8SN.10, wt Integrated SCneo AA8 275.05 >1000 ND This study
AA8SN.12 recombination reporter (hyg
R) 290.46 >1000 ND
ERCC1.17, wt Integrated DRneo UV4DR7 164.41 >1000 6.97 (22)
ERCC1.21 recombination reporter (hyg
R)+
ERCC1 expressing vector
164.70 >1000 ND
irs1SF XRCC3
  XRCC3
 , deﬁcient in HR AA8 1.36 ND ND (35)
PEF7 ERCC1
  integrated DRneo recombination
reporter (hyg
R) + empty vector
UV4DR7 1.49 61.24 0.33 (22)
S8DN4 wt Integrated DRneo recombination
reporter (hyg
R)
SPD8 ND 919.64 ND (22)
UV4DR7 ERCC1
  Integrated DRneo recombination
reporter (hyg
R)
AA8 1.45 77.61 0.40 (22)
V79Z wt wt Lung ND ND 8.71 (58)
V-C8 BRCA2
  BRCA2
 , deﬁcient in HR V79Z ND ND 0.08 (59)
V-C8+B2 wt Expressing BRCA2 from vector V-C8 ND ND 27.80 (59)
ND, not determined.
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Flasks with either UV4DR7, ERCC1.17, or irs1SF cell
lines, were inoculated with 4 10
6cells for 4h prior to a
24h treatment with hydroxyurea (2mM), 24-h treatment
with Aphidocolin (3mM), 4-h treatment with MMC (0.5,
5, 10mM), or 24-h treatment with Aphidocolin (3mM) in
addition to a 4-h treatment with MMC (10mM). After
treatment, the cells were released from the ﬂask by
trypsinization and 1 10
6cells were set into each
agarose plug (75ml, 1% InCert Agarose, BMA). Inserts
were incubated in 0.5M EDTA, 1% N-laurylsarcosyl and
proteinase K (1mg/ml) at room temperature for 48h and
thereafter washed four times in TE-buﬀer prior to loading
onto an agarose separation gel (1% chromosomal grade
agarose, Bio-Rad). Separation was performed on a CHEF
DR III equipment (BioRad; 120_ ﬁeld angle, 240s switch
time, 4V/cm, 14 C) for 18h. The gel was stained with
ethidium bromide overnight and subsequently analysed
by scanning ﬂuorescence reader (FLA-3000, Fujiﬁlm)
using Image Gauge software.
Measurement of NER as incision mediated strand breaks
The incisions during the NER process generate SSBs that
will give rise to single-stranded DNA (ssDNA) when
treated with alkaline. Not incised labeled DNA is
expected to be double stranded (dsDNA). The levels of
NER in the samples were estimated by the ratio of
ssDNA to dsDNA at a given UV- or MMC-dose.
Chinese hamster AA8 and UV4 cells with homo-
genously radiolabeled (3H-TdR, 7.4kBq/ml) DNA were
incubated with hydroxyurea (HU, 2mM) and cytosine
arabinocide (AraC, 20mM) in DMEM for 30min prior
to UV-exposure in order to inhibit the polymerization
step in NER. The amount of ssDNA was measured after
1-h post-treatment with HU/AraC by the alkaline DNA
unwinding technique as described elsewhere (27,28).
Replication fork elongation assay
In each well of a 24-well plate, 1 10
5cells were seeded
and incubated over night. Medium were exchanged to 1ml
of DMEM containing, 37kBq
3H-TdR, to each well and
incubated in 37 C and 5% CO2 for 30min. The labelled
cells were washed with 500ml Hanks balances salt solution
with calcium, magnesium and 5ml HEPES (HBSS
++),
the cells were then treated with MMC in 500ml
HBSS
++ 15min in 37 C. Thereafter each well was
washed with 500ml of HBSS
++ prior to incubation at
37 C in fresh DMEM for 0, 0.5, 1, 2, 4 or 6h. At the
selected time points selected cells were washed twice
with ice-cold 0.15M NaCl prior to 30min unwinding in
500ml 0.03M NaOH at 0 C in darkness. The unwinding
were ended by neutralization by adding 1ml NaH2PO4 to
each well and the samples were sonicated for 15se before
the addition of SDS to a ﬁnal concentration of 0.25% and
storage in  20 C until elution as described elsewhere (27).
Recombination assay
To avoid contamination with spontaneous G418-resistant
clones in the DRneo an SCneo recombination assays,
10
3cells from each cell lines were separately expanded to
conﬂuency on  10 diﬀerent Petri dishes for each cell line
(Ø 100mm). The spontaneous recombination frequency
was determined for each cell population by selection of
2 10
5cells/plate (Ø 100mm) seeded in G418 (100mg/
ml). Only those cell populations that did not retrieve
viable G418
R colonies were used for further recombina-
tion assays, as they have low background frequency of
spontaneous G418
R cells.
In the SCneo recombination assay, 1.5 10
6 cells of
each cell line (51D1SC.2, 51D1SC.4, AA8SN.6,
AA8SN.10 and AA8SN.12) were seeded over night, and
transiently transfected with or without pCMV3xnls-I-SceI
expression vector (1mg) according to manufacturer’s
protocol (Lipofectamine2000
TM, Invitrogen) to create
DSBs. After 5h of incubation in the humidiﬁed 5%
CO2/37 C incubator, cells were changed to complete
medium. Twenty-four hours after transfection, the cells
were trypsinized and counted.
In the ICL recombination assay, 1.5 10
6cells of each
cell line (UV4DR7, S8DN.4, ERCC1.17, ERCC1.21 and
PEF7) were seeded over night. Then S8DN.4, ERCC1.17
and ERCC1.21 were treated with 0nM, 200nM and
400nM of MMC, while the UV4DR7 and PEF7 were
treated with 0nM, 2nM, 5nM and 10nM MMC. After
24h, the cells were trypsinized and counted.
For recombination frequency, 2 10
5cells/plate
(Ø 100mm) were seeded and G418 (100mg/ml) was
added for selection to both treated and untreated plates.
To determine the cloning eﬃciency, 500 cells/plate were
seeded. Plates were incubated for 7 or 10 days for cloning
and selection, respectively, after which they were ﬁxed and
stained with 0.4% methylene blue in methanol.
Immunoﬂuorescence
0.3 10
6 of ERCC1.17 and PEF7 cells were plated onto
coverslips and grown for 4h before treatment, with
100nM cisplatin or 10mM MMC, or overnight if to be
untreated. The medium was removed, the coverslips
rinsed once in PBS (37 C) and ﬁxed in 3% parafor-
maldehyde in PBS-T (PBS containing 0.1% Triton
X-100) for 20min. The coverslips were rinsed once in
PBS-T prior to incubation with primary antibody, rabbit
polyclonal anti- RAD51 (H-250, Santa Cruz) at a dilution
of 1:1000, for 16h at 4 C. The coverslips were then rinsed
4 15min in PBS-T after which they were incubated
for 1h at room temperature with the secondary antibody,
Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed)
at a concentration of 1:500, and then they were rinsed
4 15min in PBS-T. The coverslips were then covered
with SlowFade Antifade Kit (Molecular Probes). The
DNA was stained with 1mg/ml To Pro (Molecular
Probes). The coverslips were then mounted on slides and
sealed with nail varnish (slides were stored in the dark).
Images were obtained using a Zeiss LSM 510 inverted
confocal microscope using a planapochromat 633/NA
1.4 oil immersion objective, and excitation wavelengths
546 and 630nm.
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SQ20B cells were used at  70–80% conﬂuency. siRNA
targeting ERCC1 (siGENOME 006311) and XRCC3
(siGENOME 012067) were obtained from Dharmacon.
siCONTROL Non-Targeting siRNA #2 (D-001210-
02-20) from Dharmacon was used as the nontargeting
control (NT). siRNAs were resuspended following manu-
facturer’s protocol. Transfection was carried out in 6-well
plates (3ml per well) using optimized transfection
conditions and Dharmacon’s reverse transfection proce-
dure. Seventy-ﬁve microliters of 2mM siRNAs were used
per transfection. Dharmafect1 was used at 2.25ml per
transfection. Cells were counted and resuspended in anti-
biotic free complete medium, and added to the siRNA/
Dharmafect mix at 96000 cells per well. Cells were
changed to normal medium 24h after transfection.
Forty-eight hours after transfection, cells were trypsi-
nized, diluted to the appropriate cell density, plated in
60-mm dishes and allowed to adhere to culture dishes
before exposure to drugs. Western blot was performed
to check for knockdown. Cisplatin was prepared fresh
and dissolved in 0.9% NaCl solution. Cisplatin and
Mitomycin C at predetermined concentrations were
added to the dishes for 2h before changing to drug-free
medium. Colonies were stained and counted  14 days
after treatment.
Western blot analysis
Cells were washed twice with ice-cold PBS and lysed by
adding RIPA buﬀer with protease inhibitors (Complete
Mini, Roche). Samples were kept on ice for 5min and
lysate were gathered using a cell scraper. Lysate were
centrifuged at 14000g for 15min at 4 C, and stored at
 80 C until analyzed. The protein concentration in the
samples was determined by bicinchoninic acid protein
assay (Pierce). Samples containing equal amounts of
protein were run on Invitrogen Novex 10% Bis–Tris gels
with MOPS running buﬀer and blotted onto nitrocellulose
membranes. Membranes were blocked in PBS containing
0.1% Tween-20 and 5% milk before the addition of
primary antibody. Membranes were probed with
antibody directed against ERCC1 (Clone 3H11, Thermo
Scientiﬁc) at 1:133 dilution or with antibody directed
against XRCC3 (NB100-165SS, Novus Biologicals) at
1:5000 dilution or b-actin (clone AC-15, Sigma) at
1:4000 dilution. Detection of antibody binding was done
using the enhanced chemiluminescence detection kit
(Amersham) using the appropriate secondary antibody.
(V-C8, V-C8+B2, V79Z, AA8SN.10, AA8SN.12,
51D1SC.2, 51D1SC.4, UV4DR7, ERCC1.17, ERCC1.21
and PEF7).
RESULTS
RAD51D mutated cells have a defect in homology-directed
repair of DNA DSBs
Use of the RAD51D
 /  cells generated through a
knockout approach in wild type CHO cells (29) provides
a strong model system for DNA repair studies, as these
isogenic mutants do not have the phenotypic complica-
tions associated with the random mutagenesis used to
create other CHO DNA repair mutants. However,
although these cells show similar phenotypes to other
RAD51 paralogue mutant hamster cells, their HR proﬁ-
ciency has not been tested directly in a chromosomally
integrated recombination reporter construct. Here,
we transfected the SCneo recombination reporter
(Figure 1A) (30) through electroporation into the
RAD51D-defecient CHO cells, 51D1, and parental AA8
cell lines and isolated independent hygromycin-resistant
clones stably carrying a single copy of the SCneo
reporter; 51D1SC.2 and 51D1SC.4 from 51D1 cells and
AA8SN.6, AA8SN.10 and AA8SN.12 from AA8 cells.
To trigger HR in the SCneo substrate, we transiently
transfected cells with the pCMV3xnlsISceI vector
expressing the I-SceI restriction endonuclease to induce a
speciﬁc DSB in the SCneo substrate. A functional neo
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Figure 1. RAD51D cells are deﬁcient in homologous recombination.
(A) Schematic illustration of the SCneo recombination substrate.
The SCneo substrate contains two non-functional copies of the neo
R
gene. After an I-SceI induced DSB, a functional neo
R gene arises by
HR via intrachromatid pairing or sister chromatid pairing. Single-
strand annealing (SSA), a non-conservative HR sub-pathway, does
not produce a functional neo
R gene (60). (B) Recombination frequency
to G418 resistance after transient transfection of the pCMV3xnlsI-SceI
vector. Resistance to G418 reﬂects a recombination event of either
intrachromatid pairing or sister chromatid pairing but not SSA.
Columns depict the average and bars represent the standard deviation
of at least three experiments.
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using G418. We found that RAD51D
–/– clones have an
11–17-fold decrease in the recombination frequency when
compared to wild-type AA8 clones (Figure 1B), showing
that RAD51D is required for HR in mammalian cells, and
verifying that these isogenic cells are useful as a model for
HR deﬁciency in CHO cells.
Diﬀerential sensitivity to cross-linkers in ERCC1-defective
and HR-defective cells
It has long been understood that ICL agents trigger HR
in mammalian cells (31) and that recombination-defective
cells show an extreme hypersensitivity to such cross-
linkers (32,33). Similarly, it has been shown that
ERCC1-defective cells are hypersensitive to cross-linkers
(34) and that ERCC1 may play a role in ICL repair
separate to that of its function in NER (16). Here, we
conﬁrm that both ERCC1- and HR-defective
RAD51D
–/– cells are hypersensitive to the cross-linkers
mitomycin C, cisplatin and melphalan (Figure 2). We
ﬁnd that ERCC1 mutated cells are more sensitive to
mitomycin C and cisplatin as compared to RAD51D
–/–
cells (Figure 2A and B), suggesting that HR and
ERCC1 may have distinct roles in repair of mitomycin
C-induced DNA lesions. This is likely depending on a
separate role for the ERCC1 in repair of the intra-cross-
links produced by mitomycin C and cisplatin that are
repaired by NER (5,6). On the contrary to this, we ﬁnd
that RAD51D
–/– and BRCA2-defective V-C8 cells are
more sensitive to melphalan than the ERCC1-defective
cells (Figure 1C), which conﬁrms an earlier ﬁnding that
XRCC3-defective cells are more sensitive than ERCC1-
defective cells to this drug (35). These data support the
diﬀerential use of DNA repair pathways when repairing
diﬀerent cross-link lesions. Furthermore, the data suggest
that HR and ERCC1 have distinct roles in ICL repair,
which may or may not be overlapping.
Mitomycin C-induced DSBs are independent of
ERCC1-XPF and HR, but require active replication
elongation
It is established that ICLs are converted into DSBs during
repair in mammalian cells, although the extent of DSB
formation varies widely between diﬀerent crosslinkers
(36). It has previously been demonstrated that the
Mus81–Eme1 complex is involved in converting ICLs
into DSBs (37) independently to the ERCC1–XPF
endonuclease activity (16,20). Here, we examined the
DSBs induced by mitomycin C in HR-defective irs1SF
[XRCC3 mutated (38)] and ERCC1 mutated UV4DR7
cells and compared with the UV4DR7 cells complemented
to a vector expressing wild-type ERCC1, ERCC1.17 (22).
We found a dose-dependent increase in DSBs following a
4-h treatment with mitomycin C (Figure 3) and that DSBs
were induced in ERCC1 mutated cells with equal eﬃ-
ciency, as compared to ERCC1 complemented cells,
which was in agreement with previous observations
(16,20). We also found that DSBs were produced equally
eﬃciently in HR-defective irs1SF cells.
It has previously been shown that DSBs are only
formed by cross-linkers in S-phase cells (16,20), suggesting
that they occur at crosslink-stalled replication forks. Here,
we wanted to test if DSB formation also requires an active
polymerase elongating the replication fork. To test this
we inhibited replication elongation with the replication
inhibitor aphidicolin, which speciﬁcally inhibits DNA
polymerase a (39).
We found fewer DSBs when co-incubating mitomycin
C and aphidicolin as compared with treatment with
mitomycin C alone, showing that replication elongation
is a requirement for converting most ICLs into a DSB
(Figure 4). Furthermore, we found that replication elon-
gation was required for mitomycin C-induced DSBs
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Figure 2. ERCC1- and RAD51D-defective cells are hypersensitive
to cross-linking agents mitomycin C and cisplatin. Survival was deter-
mined in colony outgrowth experiments in UV4DR7 (ERCC1 mutated)
and ERCC1 complemented cells (ERCC1.17, ERCC1.21) or transfec-
tion with empty vector (PEF7), along with wild-type AA8 cells
(AA8SN.10, AA8SN.12) or RAD51D targeted cells (51D1SC.2,
51D1SC.4) (26) as well as BRCA2-defective V-C8 cells and wild-type
(V79Z) or BRCA2 complemented control (V-C8+B2) (59) following
treatment with (A) mitomycin C (MMC) (B), cisplatin or (C)
melphalan. The average and standard deviation of at least three experi-
ments is depicted.
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repair pathways act downstream of DSB formation.
Mitomycin C inhibits replication fork elongation
Our data suggest that the elongating replication fork hits a
MMC-induced DNA lesion that is then converted to
DSBs. Such a model suggests that replication elongation
is inhibited by MMC. Here, we wanted to test if replica-
tion elongation is slowed down with MMC. To test this,
we used a method that uses the single-stranded DNA ends
at a replication fork as starting points for DNA unwind-
ing in alkaline solution (40). The cells were pulse-labelled
for 30min with
3H-thymidine and the speed of replication
fork elongation is monitored as the time required for
the labelled DNA to be progressed into the double-
stranded DNA fraction following alkaline unwinding
(Figure 5A). We treated cells with MMC for 15min and
followed replication elongation and found that replication
elongation is inhibited by MMC (Figure 5B). We then
tested if the decrease of replication elongation is
depending on MMC dose and found that replication elon-
gation is increasingly inhibited with an increased dose
(Figure 5C).
NER does not incise Mitomycin C or cisplatin-induced
DNA lesions
It is possible to envision two nonexclusive models for DSB
formation of an ICL lesion at a replication fork. The
ﬁrst model would be that NER incises the ICL in an
attempt to repair the lesion (19), but fails as a consequence
of the opposing strands being covalently cross-linked.
The incised ICL lesion, which includes a DNA SSB (19),
could then be encountered by an oncoming replication
fork and convert the SSB into a one-sided DSB, similarly
to the conversion of a camptothecin stabilized topoiso-
merase I complex into a one-ended DSB (41,42). This
model is supported by the results showing replication
elongation is required for DSB formation (Figure 4). An
alternative nonexclusive model is that the replication fork
is stalled at the cross-link lesion and awaits endonucleases
to convert the stalled fork into a DSB, as suggested by the
requirement for Mus81 for mitomycin C-induced DSBs
(37), which is mediated by Snm1B (43). In an attempt to
distinguish between these two distinct models of ICL
repair, we quantiﬁed global genome NER-associated
incisions following mitomycin C treatment. We added
hydroxyurea and cytosine arabinocide to cells to prevent
NER polymerization and ligation of any incised SSBs
after mitomycin C exposures, and then used the alkaline
DNA unwinding assay, which detects SSBs (27). As
expected using this method we found robust accumulation
of SSBs in wild-type AA8 cells following exposure to UVC
treatments (Figure 6A), as these cells are proﬁcient in
global genome repair of UV lesions. In contrast, ERCC1
defective UV4 cells were unable to incise the UVC lesion
(Figure 6B) as a result of their endonuclease defect.
Interestingly, we found no SSB accumulation in wild-
type AA8 cells following treatment with mitomycin C or
cisplatin, showing no detectible level of NER incision by
mitomycin C or cisplatin-induced DNA lesions (Figure 6C
and D). These results are in contrast to data showing that
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Nucleic Acids Research, 2009,Vol.37, No. 19 6405ICL are excised by NER, in transcribed sequences on
extrachromosomal plasmids (6). It is important to point
out that we are only measuring incisions globally and are
unable to detect few incisions in transcribed DNA. The
ADU technique used here utilises the separation of the
strands in order to detect the incised SSB. Thus, an ICL
would prevent the unwinding in the direction across the
ICL, but proceed normally in the opposite direction.
To obtain an accurate estimation of the NER incisions
of ICL as compared with UV lesions the mitomycin C
incisions need to be multiplied by two. However, we
cannot detect any ssDNA induced following mitomycin
C treatments, which would have been expected if NER
would incise at the mitomycin C-induced DNA lesions.
Altogether, these data suggest that mitomycin C-induced
DSBs occur enzymatically after the replication fork stalls
rather than following replication run oﬀ at NER incised
DNA lesions.
ERCC1-XPF endonuclease is not required for RAD51
foci formation, but essential for completion of mitomycin
C-induced HR
Since ERCC1-defective cells are more sensitive to ICLs
than cells mutated in other NER genes, it is suggested
that the role of ERCC1–XPF in ICL is separate from its
role in NER (16,25). Our data, showing that mitomycin
C-induced DNA lesions are poor substrates for NER,
support this notion. ERCC1–XPF does have a role in
single-strand annealing and gene conversion during HR
(22), as well as a role in micro-homology-mediated end
joining of DSBs (44), two functions for this protein
complex that may be particularly important in the
process of ICL repair. The RAD51 protein catalyzes the
strand invasion process during HR and is relocated into
nuclear foci following DNA damage (45). It is well estab-
lished that proteins involved in HR (e.g. RAD51 paralogs
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Nucleic Acids Research, 2009,Vol.37, No. 19 6407and BRCA2) are required for RAD51 foci formation
(46,47). Here, we ﬁnd that RAD51 foci form in response
to both cisplatin and mitomycin C (Figure 7), in agree-
ment with that HR is important in repair of cross-link
lesions (48,49). Furthermore, we ﬁnd that ERCC1-
defective UV4DR.7 cells form RAD51 foci equally well
as the same cells complemented with wild-type ERCC1
(Figure 7B), suggesting that ERCC1 is not critical for
RAD51 loading at DSBs and initiation of HR.
Although RAD51 foci form in ERCC1-defective cells, it
is possible that the completion of ICL-induced HR is
impaired. To test this, we investigated HR induced by
mitomycin C in the ERCC1-defective UV4DR.7 cell line
that also carry the DRneo recombination reporter (22).
ERCC1-defective UV4DR.7 cells are only partially defec-
tive in an I-SceI-induced DSB, which is explained by
ERCC1 being involved in completion of a subset of
recombination events when 30 ssDNA ﬂaps are formed
(22). Here, we investigated the recombination frequency
induced by mitomycin C and found that HR is not
induced in ERCC1-defective UV4DR.7 or in the
plasmid control transfected PEF7 clone (Figure 8). In
contrast, equally toxic doses of mitomycin C triggered
HR in the ERCC1.17 and ERCC1.21 clones (derived
from UVDR.7 cells complemented with an ERCC1
WT
expression vector) to a similar extent as in the wild-type
S8DN.4 cells carrying the DRneo substrate. These results
are in agreement with Zhang and co-workers (50), who
reported that ICL-induced recombination is impaired in
ERCC1 defective cells, using an extra-chromosomal
plasmid-based assay.
The ERCC1-XPF endonuclease functions in the same
pathway as HR in ICL repair
Since cells defective in ERCC1 appeared to initiate HR in
a normal manner after ICL exposure, we wished to deter-
mine if ERCC1 might play a role during late stages of HR,
after the formation of RAD51 nucleoprotein ﬁlaments.
To test the possibility that the ICL repair function of
ERCC1–XPF functions in concert with HR repair, we
used siRNA to knock down the expression of ERCC1,
XRCC3 and ERCC1 together with XRCC3 in SQ20B
cancer cells of the human head and neck (Figure 9A)
and investigated the clonogenic survival following
treatments with cisplatin (Figure 9B). We found that
both XRCC3 and ERCC1 siRNA depletion individually
decreased clonogenic survival to cisplatin, in agreement
with the sensitivity of the hamster cells defective in HR
and ERCC1 (Figure 1). Furthermore, we found no
additive eﬀect of depleting XRCC3 in already ERCC1
siRNA-depleted cells, strongly suggesting that the two
proteins act through the same pathway to promote
survival in these cells. We found a slight increased
survival to cisplatin in the XRCC3- and ERCC1-double-
depleted cells. However, this is entirely explained by loss
of viability in XRCC3 and ERCC1 siRNA-double-
depleted cells and not a result of decreased sensitivity to
cisplatin.
Interestingly, siRNA depletion of ERCC1 showed a
more severe eﬀect on clonogenic survival after exposure
to cisplatin as compared to siRNA depletion of XRCC3,
in agreement with survival studies comparing ERCC1-
defective hamster cells with the HR-defective RAD51D-
deﬁcient cells (Figure 1B). These data highlight an addi-
tional role for ERCC1 in repair of ICL-induced lesions
that is not totally explained by its role in XRCC3- or
RAD51D-mediated HR.
DISCUSSION
There are several ICL agents used in anti-cancer treatment
with a wide variety of speciﬁcities towards diﬀerent types
of tumours. For instance, cisplatin is highly eﬃcient in
treatment of testicular cancer, while other ICL agents
are less eﬀective (51). The reason for the diﬀerence in
anti-cancer activity most likely depends on the particular
types of DNA lesions formed. For instance, cisplatin does
not form detectible DSBs, in contrast to mitomycin C
(7,16). In this study we show that ERCC1-defective cells
are more sensitive to mitomycin C and cisplatin than HR
defective cells and that the opposite is true following
treatments with melphalan (Figure 1). This observation
underscores the diﬀerence in DNA lesions formed by
ICL agents and highlights the complex interplay between
DNA repair pathways in ICL repair that is most certainly
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Nucleic Acids Research, 2009,Vol.37, No. 19 6409unique in recognition and repair of each type of ICL
lesion. It also suggests that, at least for lesions induced
by mitomycin C, the role of ERCC1–XPF in ICL repair
is not simply within a sub-pathway of HR repair. Indeed,
ERCC1 has been shown to have a role in recombination-
independent ICL repair, supporting this notion (6).
Previous studies have established that the formation of
DSBs by ICL agents is linked with replication during the
S-phase of the cell cycle (3,16,20,35,52). Here, we conﬁrm
these results and show that mitomycin C-induced DSBs
are prevented by arrest of replication elongation. It has
been shown that NER is able to incise at cross-links
in vitro (19) and it has then been proposed that the
associated SSBs may collapse replication forks into a
one-sided DSB. Here, we show that global genome NER
is unable to incise mitomycin C-induced DNA lesions in
wild-type cells (Figure 7C), which argues against such a
replication run-oﬀ model. Instead, our data support a
model where the replication fork is ﬁrst stalled by the
ICL lesion, and then processed into a DSB, which is
supported by Mus81 being required for mitomycin
C-induced DSBs (37).
Interestingly, we ﬁnd that the ICL-inhibition of replica-
tion elongation is not as eﬃcient as equitoxic doses of
UV damage (27). Thus, decreased BrdU incorporation
in ICL-treated cells is explained primarily by loss of rep-
lication initiation rather than eﬃcient inhibition of repli-
cation elongation.
Although we do not see any global genome wide NER
incisions, it has previously been shown that ICL repair
occurs on transcribed DNA independently of recombina-
tion, which obviously would require NER incision.
This recombination-independent ICL repair requires
CSA and CSB proteins that are exclusively involved
in transcription-coupled repair (TCR) (6). Thus, we
conclude that ICL lesions can be detected and incised in
a transcription-dependent manner, which would be
conﬁned to transcribed DNA. This is also supported by
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6410 Nucleic Acids Research, 2009,Vol.37, No. 19the insensitivity of GGR defective XPC cells to the toxic
eﬀects of cisplatin (53).
The ERCC1–XPF complex is implicated in HR (21–24)
and it has been suggested that this is the role for ERCC1–
XPF in ICL repair (25,35,50). Here, we report that
ERCC1-defective cells are proﬁcient in forming RAD51
foci after cisplatin or mitomycin C treatments. This
suggests that HR is initiated normally in ERCC1-defective
cells, the ERCC1–XPF being likely to have a role in HR in
a step subsequent to the activities of the HR proteins
RAD51D, XRCC3 or BRCA2, as those mutant cells are
deﬁcient in RAD51 foci formation (46,47). Using a recom-
bination reporter, we also found that ERCC1 mutant cells
are impaired in mitomycin C-induced HR, and that the
defect can be reverted by introduction of a functional
ERCC1 gene expressed from a vector. These results are
in agreement with previous data showing that ERCC1
is required for ICL-induced recombination on an extra-
chromosomal plasmid (50). The complete deﬁciency of
ERCC1 mutant cells to induce HR after mitomycin C
treatment is not a simple reﬂection of ERCC1–XPF
being required for all types of HR events, as a two-
ended I-SceI-induced DSB still triggers recombination
100-fold in the UV4DR.7 cells (22). Thus, it is likely
that the ERCC1–XPF complex is speciﬁcally involved in
ICL-induced HR, likely involved in resolving late-stage
recombination products. The double siRNA knockout
experiment with ERCC1 and XRCC3 (Figure 9)
provides strong evidence that ERCC1 and HR function
in the same ICL repair pathway, and that additional
knockdown of XRCC3 in already ERCC1-depleted cells
shows no additional decrease in clonogenic survival.
The diﬀerential survival of ERCC1- and HR-defective
cells to mitomycin C/cisplatin and melphalan (Figure 2)
highlights the evidence that the ERCC1–XPF complex has
additional roles in ICL repair beyond resolution of HR
products, as discussed above. This is also supported by
increased sensitivity to cisplatin in ERCC1 siRNA-
depleted cells as compared with XRCC3-depleted cells
(Figure 9). We speculate that a possible role for ERCC1
could be to unhook the ICL to allow TLS bypass (Figure
10). Theoretically, this could also be done by Mus81, but
if the enzyme were to cut the stalled fork with the same
polarity as the ﬁrst stalled fork, the ICL would not be
released to allow TLS.
In conclusion, we would like to present a model for ICL
repair in mammalian cells (Figure 10), pointing out that
ICL repair is initiated when either a replication forks or
RNA polymerase runs into a ICL lesion. We also want to
point out that diﬀerent ICL agents cause diﬀerent distor-
tion to DNA and that this model is likely not true for all
ICL agents. In replication-initiated ICL repair, replication
forks will stall at the ICL lesion and the initial DSB is
catalysed by Mus81 (37) and not by replication run oﬀ.
The released one-sided DSB is likely resected by the
Mre11-RAD50-Nbs1 complex (54) and subsequently
coated with the RAD51 protein. An opposing second rep-
lication fork likely arrives at the crosslink (55), and the
ERCC1–XPF complex could unhook this replication fork
to allow TLS, possibly with Rev1 or Polz (56). The ligated
DNA molecule would be invaded by RAD51 to initiate
synthesis-dependent strand annealing (57) and the ﬁnal
lesion removed by NER. In transcription-initiated ICL
repair, ICL lesions are recognised by the RNA poly-
merase, as TCR factors are required for recombination-
independent ICL repair in absence of global genome wide
NER incision. This would recruit NER factors for both
ﬁrst and second incision, but would not generate a DSB
intermediate.
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